(BUSINESS WIRE) – St. Jude Medical, Inc. today announced the new executive leadership team that incoming President and Chief Executive Officer (CEO) Michael T. Rousseau has chosen to lead the organization into the next phase of growth and innovation. Effective Jan. 1, 2016, the new team alignment leverages the Company’s deep bench of talent and ensures the continuity of key leadership positions within St. Jude Medical.
“We are fortunate to have an executive team that’s uniquely qualified to continue St. Jude Medical’s growth story,” Rousseau said. “This is a remarkable team with a diverse set of experiences and a proven track record that will allow us to continue to transform and diversify the way we develop medical technologies in order to improve the care for patients around the world. Over the past several years, our executive team has made significant contributions to the business and shares in the excitement of the future of St. Jude Medical.”
The executive leadership team will include a new structure intended to drive organizational effectiveness and maximize the depth of experience of St. Jude Medical leaders. No changes, other than one addition, will be made to the current roster of St. Jude Medical Executive Officers. The following officers will report to Rousseau, effective Jan. 1, 2016:
Source: St. Jude Medical
CureVac and the University of Texas’s MD Anderson Cancer Center have announced a co-development and licensing agreement to develop novel messenger ribonucleic acid (mRNA)-based cancer vaccines. The strategic collaboration will focus on the development of differentiated cancer vaccine candidates in selected haematological and solid tumour indications with high unmet medical needs.
FUJIFILM Corporation is planning to invest $1.2 billion to expand the planned FUJIFILM Diosynth Biotechnologies manufacturing facility in Holly Springs, North Carolina, US. This news follows the organisation’s announcement of a $2 billion investment in the facility in March 2021. This additional financial boost totals the investment to over $3.2 billion, FUJIFILM confirmed.
Sanofi’s global restructuring and downsizing is now fully underway, with layoffs stretching to the company’s Belgian offices. Belgian newspaper De Tijd reports that 67 employees have been laid off at a site in Ghent and 32 jobs are on the chopping block at Sanofi’s Belgium HQ in Diegem.
